The aim of the trial was to estimate the efficacy of FOLOTYN compared to that of erlotinib as assessed by overall survival. The principal endpoint of the trial was overall survival. Secondary endpoints included progression-free response and survival price, both in comparison to erlotinib, and the protection and tolerability of FOLOTYN. Presentation details are as follows: Presentation Date/Time: Monday, October 11, 13:15 – 14:30 CEST Poster Name: ‘Randomized Phase 2b Study of Pralatrexate vs Erlotinib in Sufferers with Stage IIIB/IV Non-small Cell Lung Cancer after Failure of Prior Platinum-Based Therapy’ First Writer: K.According to the researchers, false-positive findings had been uncommon. ‘Surgical intervention for a non-lung cancer diagnosis was rare – – five out of just one 1,654 sufferers or 0.3 %,’ study co-leader Bryan Walker stated in a news release from The Society of Thoracic Surgeons. ‘That incidence is comparable to the 0.62 % rate within the National Lung Screening Trial that helped secure screening coverage in the U.S.,’ he described. The Lahey team said that – – if deemed suspicious – – the results of the CT screen were assessed by a multidisciplinary band of experts, including surgeons, who gave recommendations concerning next steps.